Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Total Liabilities (2017 - 2025)

Serina Therapeutics' Total Liabilities history spans 9 years, with the latest figure at $10.7 million for Q3 2025.

  • For Q3 2025, Total Liabilities fell 22.96% year-over-year to $10.7 million; the TTM value through Sep 2025 reached $10.7 million, down 22.96%, while the annual FY2024 figure was $6.1 million, 25.22% up from the prior year.
  • Total Liabilities for Q3 2025 was $10.7 million at Serina Therapeutics, up from -$1.6 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $34.6 million in Q2 2023 and bottomed at -$1.6 million in Q2 2025.
  • The 5-year median for Total Liabilities is $13.8 million (2024), against an average of $14.1 million.
  • The largest annual shift saw Total Liabilities skyrocketed 254.84% in 2024 before it tumbled 106.07% in 2025.
  • A 5-year view of Total Liabilities shows it stood at $15.0 million in 2021, then soared by 36.78% to $20.6 million in 2022, then crashed by 76.37% to $4.9 million in 2023, then rose by 25.22% to $6.1 million in 2024, then soared by 75.13% to $10.7 million in 2025.
  • Per Business Quant, the three most recent readings for SER's Total Liabilities are $10.7 million (Q3 2025), -$1.6 million (Q2 2025), and $5.2 million (Q1 2025).